Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2003

View Archived Issues

FluINsure shows positive results in influenza challenge study

Twice-daily schedule suggested for fampridine-SR in patients with chronic SCI

Astex achieves milestone in Alzheimer's drug discovery collaboration

CAT and Genzyme strengthen drug development collaboration

DepoMed acquires exclusive rights to novel gabapentin formulation

Phase IIa study initiated with SPI-8811 for cystic fibrosis

Alnylam enters RNAi-based therapy collaboration with Stanford University

Pivotal trial for Hunter's syndrome begins dosing

New formulation of Singulair available for young children with asthma

FDA grants satraplatin fast track designation

New antiangiogenic agents and their use patented by EntreMed

Takeda presents new GnRH antagonists for cancer, prostatic hypertrophy, etc.

Dainippon scientists prepare and test novel glucagon antagonists

New antifungal agents in early development at Daiichi

Novel agents for urinary incontinence described by Mochida and Asahi Glass

New CDK inhibitors in BMS development pipeline

Phase IIIa study of Neutralase halted

FDA accepts filing for DepoMorphine

Lumiracoxib approved by the MHRA for osteoarthritis and other indications

New CCR3 antagonist with oral activity in animal model of atopic dermatitis

3DP presents new orally active thrombin inhibitors at ACS meeting

Development of potent, selective cPLA2alpha inhibitors as antiinflammatory/analgesic agents

BMS discovers selective, orally active TACE inhibitors with antiinflammatory activity

RPR-749 is safe and lowers FFA levels in first human trial

Influenza virus neuraminidase inhibitor R-118958 and its active metabolite characterized by Sankyo

Good safety and PK profile emerges for CC-8490 in healthy volunteers

Tolvaptan preserves renal function in patients with congestive heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...